


2008: CANCER DRUGS IN DEVELOPMENT

Hindsight is 20/20 Foresight is 1/10,000

MEDICINES IN DEVELOPMENT FOR CANCER



Abbott Laboratories • Amgen Inc. • Amylin Pharmaceuticals, Inc. • Astellas Pharma US, Inc. • AstraZeneca Pharmaceuticals • Eli Lilly and Company • GlaxoSmithKline • Johnson & Johnson • Novartis Pharmaceuticals Corp. • Pfizer, Inc. • Roche • sanofi-aventis Group • Takeda Pharmaceuticals • TAP Pharmaceuticals, Inc. • Wyeth

**NEW YORK
HEALTH
PRODUCTS
COUNCIL**

www.nyhpc.org
518-452-1137

Only one out of 10,000 potential medicines investigated by America's research-based biopharmaceutical companies makes it through the exacting quest of research and development to be **approved for patient use** by the Food and Drug Administration. Very long odds. But we see it through, and make the billions in investments, to save lives and improve the very quality of life for millions.

With hindsight, making a medicine may appear rather easy to some. But nothing could blur the truth more. **Discovery demands the focused, consummate expertise of tens of thousands of skilled scientists, support staff and state-of-the-art labs.** It is all essential to sustain the flow of new treatments for you, your children, grandchildren and generations to come. As a demonstration, we thought you would be interested to see the magnitude of the more promising Cancer compounds that are currently under sharp scrutiny – some to advance from the exceptional foresights of today to the commonly seen **miracles of tomorrow.**

Save The Date!
Cancer and Diabetes –
Innovations, Opportunities
and Challenges Forum
March 5, 2008
For more info:
<http://www.nyhpc.org>